AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 192 min read$IVVD

Duke William E. sold $32K of IVVD

Duke William E. (Chief Financial Officer) sold 40,780 shares of Invivyd, Inc. (IVVD) at an average of $0.78 ($0.72–$0.84) across 2 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duke William E.
Published Aug 19, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IVVD
Neutral
medium confidence
Mentioned
$IVVD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IVVDNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone does not provide new operational or financial guidance.

03

What to watch

Insider sales can be driven by diversification, taxes, or scheduled liquidity needs; without accompanying guidance, trial, financing, or operational updates, the signal is weak.

Relevance 2/10Novelty 3/10Timing: filed Aug. 18 after trades on Aug. 17-18

Background

This is an SEC Form 4 insider transaction disclosure for Invivyd, Inc., reported by the CFO.

Company-level read

Ticker impact

$IVVDNeutralMedium confidence
Context

Invivyd CFO Duke William E. sold 40,780 shares in open-market transactions at $0.7220 to $0.8429, per Form 4 filed Aug. 18.

Expected impact

Limited, likely sentiment-only impact; any move would be small unless accompanied by other company-specific catalysts.

Evidence & confidence

Form 4 shows a planned sale (10b5-1) with modest dollar value (~$31.7k) relative to typical market caps, so the information is more about positioning than new business fundamentals.

Market effects

Sector

No clear sector read-through from a single planned insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be routine and not signal reduced confidence; traders may overreact to the headline.

Key entities

  • issuer
    Invivyd, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Duke William E.

    Chief Financial Officer who executed the sale(s).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IVVD insider trading history →

Related articles

OCT 14
$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.

investing.com1 min
OCT 14
$IVVDMedAI 8/10

Invivyd, Inc. (IVVD) Begins Phase 2 Trial of VYD2311 for Long COVID/PVS

Invivyd, Inc. (IVVD) has initiated a Phase 2 trial, FLINTLOCK, to evaluate the safety and efficacy of VYD2311, a monoclonal antibody, in treating Long COVID and Post-Vaccination Syndrome. The trial involves ~130 participants and will assess high-dose VYD2311 against a placebo over 90 days. VYD2311 has shown strong antiviral potency against SARS-CoV-2 variants. Success could open a new treatment market, addressing a significant unmet need.

tradingview.com1 min
OCT 14
$IVVDMedAI 8/10

Millions live with long COVID. A trial will test an antibody as a possible treatment.

Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.

stocktitan.net2 min
SEP 29
$IVVDMedAI 9/10

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine…

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing

SEC EDGAR 8-K2 min
SEP 29
$IVVDMedAI 8/10

Invivyd Reports VYD2311 Meets Primary Safety Endpoints In Phase 3 Trial

Invivyd (IVVD) reported that its COVID-19 monoclonal antibody VYD2311 met primary safety endpoints in the Phase 3 LIBERTY study, showing favorable safety and tolerability compared to an mRNA vaccine. The study enrolled 210 healthy adults, with 56.5% of VYD2311 recipients experiencing adverse events versus 91.4% for the vaccine. The company plans to use the data to support a BLA submission to the FDA. IVVD stock closed at $0.95, up 1.69%, and is trading at $0.99 in pre-market.

rttnews.com2 min
AUG 13
$IVVDMed

Invivyd Reports Second Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollme

SEC EDGAR 8-K6 min